Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review
Author:
Publisher
Elsevier BV
Subject
Molecular Biology,General Medicine,Biochemistry,Structural Biology
Reference268 articles.
1. Clinical blockade of PD1 and LAG3—potential mechanisms of action;Nguyen;Nat. Rev. Immunol.,2015
2. Mechanisms controlling PD-L1 expression in cancer;Cha;Mol. Cell,2019
3. Clinical trial data of anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal carcinoma: a review;Adkins;Cancer Treat. Rev.,2022
4. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis;Wang;JAMA Oncol.,2019
5. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions;Yi;Mol. Cancer,2022
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Generation of a hetero-dye-labeled Quenchbody against programmed cell death-ligand 1;Biochemical Engineering Journal;2024-02
2. Therapeutic Immunomodulation in Gastric Cancer;Cancers;2024-01-28
3. A Hybrid Nanoadjuvant Simultaneously Depresses PD‐L1/TGF‐β1 and Activates cGAS‐STING Pathway to Overcome Radio‐Immunotherapy Resistance;Advanced Materials;2024-01-22
4. Mitochondrial Disruption Nanosystem Simultaneously Depressed Programmed Death Ligand-1 and Transforming Growth Factor-β to Overcome Photodynamic Immunotherapy Resistance;ACS Nano;2024-01-16
5. Transarterial Radioembolization (TARE) in Patients with Hepatocellular Carcinoma: A Comparison of Palliative with Bridging-to-Transplant Concepts;Cancers;2024-01-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3